Top Markets
#1 Black Phoenix Black Phoenix +166.14%
#2 Islamic Coin Islamic Coin +158.06%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +32.85%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.43%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +16.82%
#9 Test Test +13.54%
#10 Palladium Network Palladium Network +11.40%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Wuhan General Group (China), Inc. Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc.

WUHN
Rank in Stocks #41554
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company,... Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
Share Price
$0.0003
Last synced: 2026-08-11
Market Cap
$16.55K
Change (1 day)
0.00%
Change (1 year)
200.00%
Country
ZA
Trade Wuhan General Group (China), Inc. (WUHN)

Category

Healthcare
Revenue for Wuhan General Group (China), Inc. (WUHN)
Revenue in Aug 2026 TTM: 0
According to Wuhan General Group (China), Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Wuhan General Group (China), Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US